StockNews.AI
NRXP
StockNews.AI
217 days

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel

1. Dr. Feifel advocates for controlled ketamine use with psychiatric supervision. 2. Kadima is planned as a flagship clinic under HOPE, pending acquisition completion. 3. NRx Pharmaceuticals aims for FDA approval for NRX-101 and NRX-100 treatments. 4. Increased media focus on ketamine may boost interest in NRx's innovations. 5. Acquisition could enhance NRx’s capacity in mental health therapies.

10m saved
Insight
Article

FAQ

Why Bullish?

The focus on ketamine therapy aligns with NRx's offerings, potentially increasing demand.

How important is it?

The acquisition of Kadima by HOPE is likely to improve NRx's market position.

Why Long Term?

Successful acquisition and integration of Kadima may yield sustained growth prospects for NRx.

Related Companies

HOPENRXP
"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field Kadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closing Dr. Feifel is expected to join HOPE as Chief Medical Innovation Officer , /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was featured as an expert in a program on ketamine entitled "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta. HOPE previously announced that Kadima is identified as the Company's planned flagship clinic acquisition, upon closing of the transaction. HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.) Dr. Feifel, a global leader in interventional psychiatry, has accepted a future role as Chief Medical Innovation Officer in conjunction with the previously announced planned acquisition of Kadima by HOPE. The acquisition is subject to completion of financial audits and standard closing conditions. In his comments, Dr. Feifel supported use the of ketamine in appropriate patients but emphasized the need for appropriate psychiatric supervision in a controlled setting - a view that HOPE wholeheartedly shares. This appearance with Dr. Gupta follows his appearance on another of Dr. Gupta's programs, "The Wild West of Ketamine Treatment" in August of last year. "The recent, tragic death of Mathew Perry underscores the need for people with depression to have access to psychiatric centers of excellence where they can receive ketamine and other advanced treatments at the highest standard of medical care," said David Feifel. "I plan to bring this same vision for use of ketamine and other interventional psychiatry treatment methods that made my clinic, Kadima, an industry gold-standard, to the HOPE network, upon joining the Company."About HOPE Therapeutics, Inc.HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional  psychiatry clinics to offer ketamine transcranial magnetic stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.About NRx Pharmaceuticals, Inc.NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obtaining financing necessary to consummate the acquisition. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.For further information:Matthew DuffyChief Business Officer, NRx PharmaceuticalsCo-Chief Executive Officer, HOPE Therapeutics, Inc.[email protected]SOURCE NRx Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News